Annual Report

Overview

The report highlights TME Pharma's GLORIA Phase 1/2 data, including a 19.9-month median overall survival result for the NOX-A12, bevacizumab and radiotherapy combination. It also reports FDA Fast Track Designation for NOX-A12 in glioblastoma and the FDA clearance of the protocol for a randomized Phase 2 trial. During 2024, the company raised € 7.6 million in gross cash through private placements, public offers and warrant exercises. The report further describes a small group workforce and the planned shift toward ophthalmology development for NOX-E36.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Publication date: 24 April 2025
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services